The Genius Scale Podcast
The Genius Scale Podcast
Podcast Description
A seasonal collection of conversations sharing the growth & scaling journeys of rising entrepreneurs & leaders both disrupting and servicing disruptors.
Podcast Insights
Content Themes
The podcast delves into themes of entrepreneurship, technology innovation, and market disruption. Episodes cover topics like responsible AI in business, the evolution of software engineering practices, and the significance of no-code solutions for startups, with examples including conversations with Rakesh David about AI adoption challenges and Jorge Lana on building a transformational business ecosystem.
If you were to speak to B2B leaders about growing business, you’d see that business growth can usually be divided into levels – and each level requires a new set of tactics or strategies to get to the next.
But we each, especially in the B2B space, also operate in some zone of genius that we aim to contribute to others. Some in saturated markets where they need to break free. Others in emerging markets where they need to achieve salient clarity.
Either way, we saw they needed a platform to speak their mind.
Which is why we started the Genius Scale podcast.
Community cancer centers treat 80% of American cancer patients but have up to 30% higher mortality rates than academic institutions. Kingsley Ndoh watched his aunt suffer through a late-stage colorectal cancer misdiagnosis in Nigeria, then discovered this disparity stems from resource constraints: community oncologists carry three times the workload with limited access to cutting-edge research and clinical trial results that academic centers implement immediately.
His solution: Hurone AI, a digital oncologist achieving 50% workload reduction and 95% protocol compliance. While competitors focus on diagnostics, Kingsley tackles the treatment decision gap with voice-activated data retrieval, real-time guideline updates, and treatment options backed by references. From piloting in Rwanda with Kinyarwanda language support to FDA approval for UCSF and Johns Hopkins, Kingsley reveals why international datasets reduce AI bias and how value-based care models are accelerating adoption of clinical decision support systems.
Key Topics
- Why community cancer centers have 30% higher mortality despite treating 80% of patients
- Building a digital oncologist with voice activation and real-time guidelines
- Engineering out hallucinations using AWS Bedrock with feedback loops
- FDA 510K approval for clinical decision support systems
- Rwanda pilot with Kinyarwanda language before US rollout
- Why international data diversity reduces AI bias in treatment
- Value-based care shifting from fee-for-service to quality metrics
Chapters
- 00:00 From Nigeria to Silicon Valley: The Personal Story Behind Hurone AI
- 04:32 The 30% Mortality Gap Between Cancer Center Types
- 09:24 Building the Digital Oncologist: Treatment Decisions vs Diagnostics
- 13:28 Engineering Out Hallucinations with AWS Bedrock
- 15:26 Navigating FDA Approval and Healthcare Regulation
- 18:00 UCSF Green Tumor Center: Piloting with Brain Cancer
- 23:53 President's Cancer Panel and Technology Policy
- 29:44 Global Testing: Rwanda Pilot and Multilingual Expansion
- 34:00 International Data Standards and Bias Reduction
- 38:00 The Ethics of AI in Healthcare: Why Symbiosis is Non-Negotiable
Keywords: Hurone AI, oncology, clinical decision support, cancer care disparity, AI healthcare, FDA approval, value-based care, precision oncology, medical AI, global health equity
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.